Navigation Links
Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset
Date:7/10/2014

Amsterdam, NL, 10 July 2014 Up to 70% of Parkinson's disease (PD) patients experience sleep problems that negatively impact their quality of life. Some patients have disturbed sleep/wake patterns such as difficulty falling asleep or staying asleep, while other patients may be subject to sudden and involuntary daytime sleep "attacks." In the extreme, PD patients may exhibit REM-sleep behavior disorder (RBD), characterized by vivid, violent dreams or dream re-enactment, even before motor symptoms appear. A review in the Journal of Parkinson's Disease discusses the underlying causes of sleep problems in PD, as well as medications, disease pathology, and comorbidities, and describes the most appropriate diagnostic tools and treatment options.

Sleep problems in PD patients can have wide-ranging adverse effects and can worsen in later stages of the disease. Sleepiness socially isolates patients and excessive sleepiness can put patients at risk of falls or injury, and can mean patients must give up driving. Sleepiness can impair cognition and concentration, exacerbate depression, and interfere with employment. Wakefulness at night impairs daytime wakefulness and may also cause mood instabilities and can exhaust caregivers.

"Diagnosis and effective treatment and management of these problems are essential for improving the quality of life and reducing institutionalization of these patients," says lead author Wiebke Schrempf, MD, Technische Universitt Dresden, Faculty of Medicine Carl Gustav Carus, Department of Neurology, Division of Neurodegenerative Diseases, Dresden, Germany.

Dr. Schrempf and colleagues describe some of the complexities associated with treating sleep problems in PD patients, such as the worsening of sleep problems by dopaminergic medications used to treat motor symptoms. Lower doses of levodopa or dopamine agonists are able to improve sleep quality partly by reducing motor symptoms such as nighttime hypokinesia (decreased body movement), dyskinesia (abnormal voluntary movements), or tremor (involuntary shaking), which interfere with normal sleep. However, the same medications may also cause excessive daytime sleepiness. The report describes how changing medication, dose, duration of treatment, or timing of administration can improve outcomes.

The presence of other conditions common in PD patients such as depression, dementia, hallucinations, and psychosis may interfere with sleep. Unfortunately, some antidepressants can also impair sleep.

Sleep problems may also be harbingers of future neurodegenerative disease. Patients with RBD exhibit intermittent loss of normal muscle relaxation during REM sleep and engage in dream enactment behavior during which they may shout, laugh, or exhibit movements like kicking and boxing. "RBD seems to be a good clinical predictor of emerging neurodegenerative diseases with a high specificity and low sensitivity, whereas other early clinical features of PD, such as olfactory dysfunction and constipation, are less specific," says Dr. Schrempf. "These early clues may help identify PD patients before motor symptoms appear, when disease-modifying therapies may be most beneficial."

PD is the second most common neurodegenerative disorder in the United States, affecting approximately one million Americans and five million people worldwide. Its prevalence is projected to double by 2030. The most characteristic symptoms are movement-related, such as involuntary shaking and muscle stiffness. Non-motor symptoms, such as worsening depression, cognition, and anxiety, olfactory dysfunction, and sleep disturbances, can appear prior to the onset of motor symptoms.


'/>"/>
Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Contradictory findings about the effect of the full moon on sleep
2. Sleep deprivation leads to symptoms of schizophrenia
3. Twin study links community socioeconomic deprivation to sleep duration
4. Short sleep, aging brain
5. Sleep, mood improves after substantial weight loss
6. Sleep education program spurs preschoolers to snooze 30 minutes longer at night
7. Does the moon affect our sleep?
8. Sleep quality and duration improve cognition in aging populations
9. Proteins causing daytime sleepiness tied to bone formation, target for osteoporosis
10. Parent and child must get enough sleep to protect against child obesity
11. Sleep apnea tied to diabetes in large study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Miami ... attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant ... will present its annual Global Symposium at the Fontainebleau Hotel located in Miami ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke ... its ANCD BRAIN device as the product advances towards regulatory and clinical phases. ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura ... the achievement of Cisco Select certification and SMB specialization. Altura is now ... , In earning the Select Certification, Altura fulfilled the training and exam ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... consumers can save an average of 70% when buying medication online from Canadian ... are available when purchasing from other countries. The report (chart below) compares U.S. ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in ... teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their primitive ... been used to remove decayed dental matter, and that teeth were then filled with ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
(Date:4/18/2017)... , April 18, 2017  Spero Therapeutics, LLC, a ... treatment of bacterial infections, will present preclinical data supporting ... of multidrug resistant (MDR) Gram-negative infections at the 27th ... April 22-25, 2017 in Vienna, Austria ... ...
Breaking Medicine Technology: